Latin America's first-in-human landscape is entering a new phase, with regulatory frameworks maturing in the region's largest market while smaller jurisdictions sharpen their case on speed. This week's edition tracks thr
first-in-human · FIH · clinical trial · clinical research · regulatory · ANVISA
Latin America's first-in-human landscape is entering a new phase, with regulatory frameworks maturing in the region's largest market while smaller jurisdictions sharpen their case on speed. This week's edition tracks three structural shifts and three operator-level data points reshaping sponsor decision-making across the region.
Brazil's ANVISA publishes its 9th Annual Report and warns of capacity strain under Lei 14.874/2024 Costa Rica formally enters the bioaccess® FIH map as the region's seventh jurisdiction RDC 1022/2026 introduces a 60-day sponsor response deadline inside the ANVISA reliance queue Argentina's 62-day approval cap goes a seventh week without empirical validation from ANMAT Avance Clinical secures Frost & Sullivan's 2026 Global Company of the Year recognition Panama's SilkAxons two-week approval continues to set the small-market benchmark
Take a closer look at how Brazil's capacity test, Costa Rica's debut, and Panama's speed model are pulling the region in different strategic directions. 👇
Brazil's Clinical Research Framework Faces Its First Operational Stress Test
ANVISA published its 9th Annual Report on Clinical Research Activities on May 16, providing the first official dataset reflecting the country's overhauled clinical research framework under Lei 14.874/2024. Beyond the headline metrics, the agency signaled directly that demand for clinical research activity is rising faster than current staffing capacity, explicitly referencing "recomposição das equipes técnicas" — the rebuilding of technical teams to manage rising submission volume. The implication for sponsors is clear: Brazil's new framework may be structurally stronger than any previous LATAM model, but execution will hinge on whether the agency can scale operationally to match the pipeline it now attracts.
Why It Matters: Brazil remains the region's most consequential clinical research story, but the focus is shifting from regulatory design to operational throughput. Sponsors building 2026-2027 LATAM strategies should price both the upside of the new framework and the near-term capacity overhang.
Costa Rica Joins the LATAM First-in-Human Map
Costa Rica formally entered the bioaccess® first-in-human landscape this week through a coordinated 12-article content launch centered on the country's clinical research infrastructure. The framework is anchored by Law 9234 and CONIS oversight, with reported approval timelines of 30 to 90 days and ethics review cycles estimated at four to eight weeks. More notably, Costa Rica is being positioned as part of a broader operational strategy for sponsors evaluating alternatives to larger jurisdictions now facing rising complexity or capacity pressure. The country becomes the seventh LATAM jurisdiction actively positioned for FIH and early-phase trials, joining Argentina, Brazil, Colombia, Mexico/Panama, Bolivia, and Chile.
Bottom Line: The LATAM FIH map is no longer a Brazil-or-Mexico binary. Seven jurisdictions now compete on differentiated combinations of speed, cost, and regulatory profile — a shift that fundamentally changes site selection strategy for early-phase sponsors.
ANVISA Tightens Sponsor Response Timelines Inside the Reliance Queue
Brazil's regulatory framework continues to evolve beyond its headline reforms. RDC 1022/2026, published May 7, amended the RDC 997/2025 reliance framework by introducing a 60-day deadline for sponsors to respond to ANVISA technical queries related to clinical research and post-registration processes. The change may appear procedural, but it signals something larger: ANVISA is actively operationalizing the reliance queue before publishing formal performance metrics. The update suggests the agency is moving toward a more disciplined, throughput-oriented review model rather than simply accelerating approvals on paper.
What to Focus On: Sponsors entering the ANVISA reliance pathway in 2026 should staff response teams with the same urgency as initial submission teams. The 60-day clock is now a critical-path item in any Brazil regulatory strategy.
Argentina's 62-Day Promise Faces a Longer Silence Argentina's 62-day clinical trial approval framework has now gone seven weeks without empirical validation. Although the cap under Disposición 7516/2025 has been active since December 2025, ANMAT has yet to publish operational data confirming whether the timeline is being achieved in practice. The absence is becoming increasingly significant. Argentina remains one of the region's most closely watched early-phase markets, and the gap between regulatory ambition and reported performance is widening as Brazil moves to publish its own metrics. For now, Argentina remains a high-potential jurisdiction whose practical execution profile is still unresolved.
Why It Matters: Sponsors counting on Argentina's 62-day cap as a strategic differentiator should build contingency timelines. Until ANMAT publishes performance data, the cap is best treated as a target rather than a planning input.
Advance Your First-in-Human Trials with Confidence bioaccess® is the world's First-in-Human CRO built for U.S. regulatory anchoring and Latin American execution. We help MedTech, Biopharma, and Radiopharma innovators compress timelines, reduce costs, and generate FDA/EMA-ready evidence — across seven active LATAM jurisdictions.
40% faster regulatory approvals across Argentina, Brazil, Colombia, Mexico/Panama, Bolivia, Chile, and Costa Rica 30% lower clinical trial costs versus US and EU benchmarks End-to-end execution from feasibility through first patient in
Schedule your first-in-human trial consultation at bioaccessla.com
Avance Clinical Raises the Global CRO Benchmark
Global competition in early-phase research is intensifying. Avance Clinical received Frost & Sullivan's 2026 Global Company of the Year recognition for the biotech CRO industry, reinforcing its positioning as a leading operator for early-phase programs. The company highlighted its "GlobalReady" model spanning the United States, Asia-Pacific, and Europe, alongside expanded oncology capabilities following its LumaBridge acquisition earlier this year.
For LATAM-focused CROs, the significance is strategic rather than geographic. As global CRO consolidation accelerates, LATAM operators are increasingly differentiating through regulatory familiarity, startup speed, and patient access rather than category branding alone.
Bottom Line: The CRO market is bifurcating into global generalists and regional specialists. LATAM-native operators that can deliver country-specific regulatory speed will retain a structural advantage in FIH and early-phase work.
Panama Remains the Small-Market Proof Point
The strongest argument for smaller LATAM jurisdictions continues to be operational speed. bioaccess®'s Costa Rica rollout repeatedly referenced the SilkAxons first-in-human implantation in Panama as a benchmark case for what smaller markets can deliver. The study secured approval in approximately two weeks and supported a world-first nerve guide implantation — a timeline difficult to replicate in larger jurisdictions.
As Brazil scales and larger markets become more operationally demanding, Panama increasingly represents the counter-model: lower complexity, faster execution, and targeted early-phase agility.
What to Focus On: For studies of 5-15 patients with tight capital runway, the small-market path through Panama, Costa Rica, El Salvador, or the Dominican Republic now offers a credible alternative to the Brazil/Mexico default.
Key Takeaways
Brazil's clinical research throughput, not its regulatory design, is now the variable to watch under Lei 14.874/2024 Costa Rica becomes the seventh active LATAM FIH jurisdiction, expanding sponsor optionality - RDC 1022/2026 imposes a 60-day sponsor response deadline that reshapes ANVISA reliance-pathway execution Argentina's 62-day cap remains unvalidated seven weeks after activation, raising planning risk - Avance Clinical's Frost & Sullivan recognition signals accelerating global CRO consolidation Panama's two-week SilkAxons approval continues to anchor the small-market speed argument The LATAM FIH map is splitting into scaled jurisdictions and agility-focused small markets
← All Global Trial Accelerators editions · Contact bioaccess®